Harbour BioMed has entered into a $105.3 million share subscription agreement with AstraZeneca to bolster its research and development capabilities in antibody therapeutics.
Target Information
Harbour BioMed (HBM Holdings, HKEX: 02142) is a biopharmaceutical company based in Hong Kong, dedicated to the discovery, development, and commercialization of innovative antibody therapeutics specifically targeting oncology and immunology. The company actively engages in cutting-edge research aimed at addressing unmet medical needs in these critical areas of healthcare.
With a strong commitment to advancing scientific knowledge, Harbour BioMed aims to deliver new therapies that improve patient outcomes. The recent share subscription agreement with AstraZeneca represents a significant step in supporting the company’s ambitious R&D initiatives and operational growth.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Hong Kong
The biopharmaceutical industry in Hong Kong has experienced substantial growth in recent years, driven by increased investments in research and development, along with a supportive regulatory en
Similar Deals
Lotus Pharmaceutical Co., Ltd. → LENZ Therapeutics, Inc.
2025
Mérieux NutriSciences → food testing business of Bureau Veritas
2024
Hikma Pharmaceuticals PLC → Takeda Pharmaceuticals International AG
2024
Sofina, Temasek, AlbionVC, Earlybird, Eight Roads Ventures, F-Prime Capital, MTIP, Various angel investors → Oviva
2023
AstraZeneca
invested in
Harbour BioMed
in 2025
in a Other deal
Disclosed details
Transaction Size: $105M